Last patient receives Mizagliflozin in Phase 2 clinical study for the treatment of post-bariatric hypoglycaemia
Vogenx has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed...